143 related articles for article (PubMed ID: 35547598)
1. All-Trans-Retinoic Acid Plus Oxaliplatin/Fluorouracil/Leucovorin for Advanced Hepatocellular Carcinoma with Pulmonary Metastasis: A Multicenter Retrospective Study.
Sun J; Liu C; Wang N; Jiang D; Zhang F; Shi J; Cheng S
Cancer Manag Res; 2022; 14():1663-1670. PubMed ID: 35547598
[TBL] [Abstract][Full Text] [Related]
2. A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study.
Sun J; Liu C; Shi J; Wang N; Jiang D; Mao F; Gu J; Zhou L; Shen L; Lau WY; Cheng S
Chin Med J (Engl); 2022 Oct; 135(19):2338-2343. PubMed ID: 36103975
[TBL] [Abstract][Full Text] [Related]
3. All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial.
Shi J; Sun J; Liu C; Chai Z; Wang N; Zhang H; Cheng S
Trials; 2019 Apr; 20(1):245. PubMed ID: 31036040
[TBL] [Abstract][Full Text] [Related]
4. Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study.
Sun J; Mao F; Liu C; Zhang F; Jiang D; Guo W; Huo L; Zhou L; Lau WY; Shi J; Cheng S
Signal Transduct Target Ther; 2023 Sep; 8(1):368. PubMed ID: 37752117
[TBL] [Abstract][Full Text] [Related]
5. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Qin S; Bai Y; Lim HY; Thongprasert S; Chao Y; Fan J; Yang TS; Bhudhisawasdi V; Kang WK; Zhou Y; Lee JH; Sun Y
J Clin Oncol; 2013 Oct; 31(28):3501-8. PubMed ID: 23980077
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
7. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
8. LABS score- a prognostic tool for FOLFOX4-treated advanced hepatocellular carcinoma and real-world efficacy: a single-center retrospective study.
Wonglhow J; Sunpaweravong P; Sathitruangsak C; Dechaphunkul A
BMC Cancer; 2024 Mar; 24(1):281. PubMed ID: 38429725
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
[TBL] [Abstract][Full Text] [Related]
11. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
12. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
[TBL] [Abstract][Full Text] [Related]
13. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
Kim GP; Sargent DJ; Mahoney MR; Rowland KM; Philip PA; Mitchell E; Mathews AP; Fitch TR; Goldberg RM; Alberts SR; Pitot HC
J Clin Oncol; 2009 Jun; 27(17):2848-54. PubMed ID: 19380443
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer.
Gravalos C; Salut A; García-Girón C; García-Carbonero R; León AI; Sevilla I; Maurel J; Esteban B; García-Rico E; Murias A; Cortés-Funes H
Clin Transl Oncol; 2012 Aug; 14(8):606-12. PubMed ID: 22855138
[TBL] [Abstract][Full Text] [Related]
15. Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study.
Lin CC; Yang TS; Yen CJ; Cheng R; Liu J; Hsu C
Oncologist; 2020 Dec; 25(12):e1921-e1929. PubMed ID: 33017497
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ueno M; Yamaguchi T
Asia Pac J Clin Oncol; 2014 Dec; 10(4):322-9. PubMed ID: 23915091
[TBL] [Abstract][Full Text] [Related]
17. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Nordlinger B; Sorbye H; Glimelius B; Poston GJ; Schlag PM; Rougier P; Bechstein WO; Primrose JN; Walpole ET; Finch-Jones M; Jaeck D; Mirza D; Parks RW; Mauer M; Tanis E; Van Cutsem E; Scheithauer W; Gruenberger T; ; ; ; ;
Lancet Oncol; 2013 Nov; 14(12):1208-15. PubMed ID: 24120480
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China.
Qin S; Kruger E; Tan SC; Cheng S; Wang N; Liang J
Cost Eff Resour Alloc; 2018; 16():29. PubMed ID: 30087583
[TBL] [Abstract][Full Text] [Related]
19. [FOLFOX4 regimen versus DP(O)F regimen for advanced gastric cancer].
Wu F; Zhang HG; Ran FW; Zhang XR; Shi YK
Ai Zheng; 2008 Apr; 27(4):413-7. PubMed ID: 18423129
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]